GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Wuhan Easy Diagnosis Biomedicine Co Ltd (SZSE:002932) » Definitions » Cyclically Adjusted Price-to-FCF

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Cyclically Adjusted Price-to-FCF : 7.33 (As of Jun. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted Price-to-FCF?

As of today (2024-06-22), Wuhan Easy Diagnosis Biomedicine Co's current share price is ¥17.88. Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 was ¥2.44. Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF for today is 7.33.

The historical rank and industry rank for Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

SZSE:002932' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 6.75   Med: 44.07   Max: 96.46
Current: 7.55

During the past 13 years, Wuhan Easy Diagnosis Biomedicine Co's highest Cyclically Adjusted Price-to-FCF was 96.46. The lowest was 6.75. And the median was 44.07.

SZSE:002932's Cyclically Adjusted Price-to-FCF is ranked better than
94.49% of 236 companies
in the Medical Devices & Instruments industry
Industry Median: 41.72 vs SZSE:002932: 7.55

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Wuhan Easy Diagnosis Biomedicine Co's adjusted free cash flow per share data of for the fiscal year that ended in Dec23 was ¥1.244. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is ¥2.44 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted Price-to-FCF Chart

Wuhan Easy Diagnosis Biomedicine Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 66.26 43.65 16.21 9.41

Wuhan Easy Diagnosis Biomedicine Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 9.41 -

Competitive Comparison of Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF falls into.



Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=17.88/2.44
=7.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Wuhan Easy Diagnosis Biomedicine Co's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec23 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=1.244/114.7809*114.7809
=1.244

Current CPI (Dec23) = 114.7809.

Wuhan Easy Diagnosis Biomedicine Co Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.086 99.000 0.100
201512 0.289 100.600 0.330
201612 0.120 102.600 0.134
201712 0.006 104.500 0.007
201812 0.035 106.500 0.038
201912 -0.045 111.200 -0.046
202012 1.588 111.500 1.635
202112 4.841 113.108 4.913
202212 16.095 115.116 16.048
202312 1.244 114.781 1.244

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Wuhan Easy Diagnosis Biomedicine Co  (SZSE:002932) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Wuhan Easy Diagnosis Biomedicine Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Wuhan Easy Diagnosis Biomedicine Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Dongxin Road, 2 Floor, Building E, International Students Pioneer Park, Guandong Science and Technology Park, Donghu Development Zone, Hubei, Wuhan, CHN, 430075
Wuhan Easy Diagnosis Biomedicine Co Ltd is engaged in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments and mobile ECG products. The company's product profile consists of Molecular diagnosis, Chemiluminescence, Blood gas analysis, and others. It also provides various other solutions such as Mingde Biomolecular Diagnostic Service Solution, Mingde Biothoracic Center Solution, POCT Solution, Remote ECG network construction solution, and others.
Executives
Wang Rui Directors, executives
Wang Jian Fei Director

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Headlines

No Headlines